IGI Logo

Alembic Pharmaceuticals is currently trading at Rs. 985.00, up by 11.75 points or 1.21% from its previous closing of Rs. 973.25 on the BSE.

The scrip opened at Rs. 983.95 and has touched a high and low of Rs. 1005.30 and Rs. 982.75 respectively. So far 12707 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1150.00 on 18-Dec-2020 and a 52 week low of Rs. 600.00 on 21-Apr-2020.

Last one week high and low of the scrip stood at Rs. 1005.30 and Rs. 945.30 respectively. The current market cap of the company is Rs. 19493.17 crore.

The promoters holding in the company stood at 69.78%, while Institutions and Non-Institutions held 17.10% and 13.12% respectively.

Alembic Pharmaceuticals’ joint venture (JV) -- Aleor Dermaceuticals (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Efinaconazole Topical Solution, 10%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Jublia Topical Solution, 10%, of Bausch Health Americas, Inc. (Bausch). Efinaconazole Topical Solution, 10% is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Efinaconazole Topical Solution, 10% has an estimated market size of $ 233 million for twelve months ending December 2020. Aleor has settled the case with Bausch Health and. will launch its generic as per the terms of settlement. Alembic has a cumulative total of 140 ANDA approvals (123 final approvals and 17 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.